Medical Cannabis Laws Seem Not to Have Affected Opioid, Nonopioid Therapy
WEDNESDAY, July 5, 2023 (HealthDay News) — Medical cannabis laws seem not to have important effects on the receipt of opioid or nonopioid pain treatment, according to a study published online July 4 in the Annals of Internal Medicine.Emma E. McGinty,…
Learn MoreAnesthesiologists Say Ozempic, Wegovy Should Be Halted Prior to Surgery
MONDAY, July 3, 2023 (HealthDay News) — The weight-loss drug Ozempic could be dangerous for a patient undergoing anesthesia, according to a new warning from the American Society of Anesthesiologists.Semaglutide (Ozempic, Wegovy) and other drugs of th…
Learn MoreBulevirtide Linked to Decline in Hepatitis D Virus RNA Levels
FRIDAY, June 30, 2023 (HealthDay News) — For patients with hepatitis D virus (HDV), bulevirtide is associated with a reduction in HDV RNA levels and alanine aminotransferase (ALT) levels, according to a study published online June 22 in the New Engla…
Learn MorePegozafermin Leads to Improvements in Fibrosis in NASH
FRIDAY, June 30, 2023 (HealthDay News) — For patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and stage F2 or F3 fibrosis, treatment with pegozafermin leads to improvements in fibrosis, according to a study published online June 24 …
Learn MoreMeds Rarely Initiated After Discharge for Alcohol Use Disorder
FRIDAY, June 30, 2023 (HealthDay News) — Patients hospitalized for alcohol use disorder (AUD) rarely initiate medications for AUD (MAUD) after discharge, according to a research letter published online June 27 in the Annals of Internal Medicine.Eden …
Learn MoreCDC: Too Many Americans Cannot Access the Cure for Hepatitis C
THURSDAY, June 29, 2023 (HealthDay News) — More than 2 million people in the United States have hepatitis C, but most are not getting the safe treatment that can cure the disease, according to research published in the June 30 issue of the U.S. Cente…
Learn MoreADA: Reductions in Body Weight With Retatrutide for Obesity
THURSDAY, June 29, 2023 (HealthDay News) — Retatrutide treatment for 48 weeks yields substantial reductions in body weight among adults with obesity, according to a study published online June 26 in the New England Journal of Medicine to coincide wit…
Learn MoreUn nuevo rival de Wegovy se muestra promisorio en ensayos clínicos
MARTES, 27 de junio de 2023 (HealthDay News) — Un medicamento experimental parece funcionar mejor que los medicamentos de moda, Wegovy y Ozempic, tanto para perder peso como para controlar la diabetes, muestran dos ensayos clínicos iniciales. La reta…
Learn MoreCrisaborole Effective for Long-Term Maintenance in Mild-to-Moderate Eczema
WEDNESDAY, June 28, 2023 (HealthDay News) — Crisaborole is effective as a long-term maintenance therapy for pediatric and adult patients with mild-to-moderate atopic dermatitis (AD), according to a study published online May 15 in the American Journa…
Learn MoreCrisaborole Effective for Long-Term Maintenance in Mild-to-Moderate Eczema
WEDNESDAY, June 28, 2023 (HealthDay News) — Crisaborole is effective as a long-term maintenance therapy for pediatric and adult patients with mild-to-moderate atopic dermatitis (AD), according to a study published online May 15 in the American Journa…
Learn More